心复康口服液对自发性高血压大鼠心肌纤维化及左室功能的影响  

Effects of Xinfukang oral liquid on myocardial fibrosis and left ventricular performance in spontaneous hypertensive rat

作　　者：李俊峡[1] 曹雪滨[2] 赵春生[1] 赵玉英[1] 

机构地区：[1]白求恩国际和平医院心内科,河北石家庄050082 [2]解放军第252医院心内科,河北保定071000

出　　处：《第四军医大学学报》2008年第17期1576-1578,共3页Journal of the Fourth Military Medical University

基　　金：国家自然科学基金重点资助项目(30130220)

摘　　要：目的:观察心复康口服液对自发性高血压大鼠(SHR)心室重构及左室功能的影响.方法:12周龄SHR 30只随机分为3组,即空白对照组(SHR-C组)、依那普利组(SHR-Y组)及心复康口服液组(SHR-X组),每组10只.并以正常SD大鼠10只作对照(SD组).治疗10wk后测定各组大鼠收缩压(SBP)、左室舒张末压(LVEDP)、最大左室压力微分值(±dp/dtmax)、心脏质量指数(HMI)、左室质量指数(LVMI)以及胶原蛋白含量和血浆血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)等指标.结果:治疗10wk后,各治疗组LVEDP,HMI,LVMI,胶原蛋白含量,AngⅡ和ALD较对照组显著降低(P<0.01),±dp/dtmax较对照组显著增大(P<0.05).结论:心复康口服液可通过抑制AngⅡ和ALD防止心肌纤维化,抑制心室重构,改善左室功能.AIM： To investigate the effects of Xinfukang oral liquid on myocardial fibrosis and left ventricular performance in spontaneous hypertensive rat（SHR）. METHODS： Twelve-week-old SHR（ n = 30） were divided randomly into 3 groups： SHR-C group （ untreated）, SHR-Y group （ treated with enalapril ） and SHR-X group （treated with the Xinfukang oral hquid ）, each group consisting of 10 rats. And 10 normal SD rats were used as the negative controls. Left ventricular end diastolic pressure （LVEDP）, systolic blood pressure （SBP）, heart mass index （HMI）, left ventricular mass index （ LVMI ）, maximal ascending and descending velocity of the left ventricular pressure （± dp/ dt max） and left ventricular collagen contents and Ang Ⅱ , ALD of plasma were determined after 10-week treatment. RESULTS： After 10-week treatment, compared with SHR-C, the LVEDP, HM1, LVM1 of SHR＊Y and SHR-X groups were significantly decreased（P 〈 0.01 or P 〈 0. 05 ） ; the ± dp/dt max of SHR-Y and SHR-X groups were increased（ P 〈 0.05 ）, the left ventricular collagen contents and Ang 11 and ALD of SHR-Y and SHR-X groups were significantly decreased （ P 〈 0. 01 or P 〈 0. 05 ）. CONCLUSION： Xinfukang oral liquid can inhibit myocardial fi- brosis and improve the function of the left ventricle.

关 键 词：心复康口服液 高血压 左心室肥大 心肌纤维化 

分 类 号：R541.4[医药卫生—心血管疾病]